Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TG 1801

Next Previous
Drug Profile

TG 1801

Alternative Names: NI-1701; TG-1801

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NovImmune SA
  • Developer Light Chain Bioscience; TG Therapeutics Inc
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I B-cell lymphoma
  • No development reported Chronic lymphocytic leukaemia

Most Recent Events

  • 06 May 2025 TG 1801 is still in phase-I trials for B-cell lymphoma (Second-line therapy or greater) in Australia (IV, Infusion) (NCT03804996) (Light Chain Bioscience pipeline, May 2025) (TG Therapeutics pipeline, May 2025)
  • 31 Jul 2024 TG Therapeutics terminates a phase Ib trial for B-cell lymphoma and Chronic lymphocytic leukaemia (Combination therapy, Monotherapy, Second-line therapy or greater) (IV) due to business decision (NCT04806035)
  • 28 May 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Combination therapy, Second-line therapy or greater) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top